VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib-a multicentric retrospective analysis

Acta Oncologica

Volumn 53, Issue 1, 2014, Pages 103-112

  Beuselinck, Benoit ^a,b   Karadimou, Alexandra ^b   Lambrechts, Diether ^c,d   Claes, Bart ^c,d   Wolter, Pascal ^a   Couchy, Gabrielle ^b   Berkers, Joost ^a   Van Poppel, Hendrik ^a   Paridaens, Robert ^a   Schöffski, Patrick ^a   Méjean, Arnaud ^e   Verkarre, Virginie ^f   Lerut, Evelyne ^a   Joly, Florence ^g   Lebret, Thierry ^h   Gravis, Gwénaelle ⁱ   Deplanque, Gael ^j   Descazeaud, Aurélien ^k   Leclercq, Nathalie Rioux ^l   Molinié, Vincent ^j   Patard, Jean Jacques ^m   Teghom, Corine ^e   Elaidi, Reza ^e   Zucman Rossi, Jessica ^b,e   Oudard, Stéphane ^b,e   more..

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Université Paris 13   (France)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g CENTRE FRANÇOIS BACLESSE   (France)

^h FOCH HOSPITAL   (France)

ⁱ INSTITUT PAOLI CALMETTES   (France)

^j Clinique St Joseph   (France)

^k DUPUYTREN UNIVERSITY HOSPITAL   (France)

^l RENNES UNIVERSITY HOSPITAL   (France)

^m BICÊTRE HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

SUNITINIB; VASCULOTROPIN RECEPTOR 1; CALCIUM; DNA; HEMOGLOBIN; LACTATE DEHYDROGENASE;

ADULT; ARTICLE; BELGIUM; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURGERY; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FRANCE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEPHRECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; CALCIUM BLOOD LEVEL; CANCER IMMUNOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; FOLLOW UP; LACTATE DEHYDROGENASE BLOOD LEVEL; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY; NEUTROPHIL COUNT; THROMBOCYTE COUNT;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PYRROLES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84890919736     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2013.770600     Document Type: Article

References (21)

1. Motzer RJ, H utson TE, T omczak P, M ichaelson MD, Bukowski RM, Rixe O, et al . Sunitinib versus interferon alfa in metastatic renal-cell carcinoma . N Engl J Med 2007 ; 356 : 115-24 (Pubitemid 46089672)
2. Motzer RJ, H utson TE, T omczak P, M ichaelson MD, Bukowski RM, Oudard S, et al . Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma . J Clin Oncol 2009 ; 27 : 3584-90
3. Rini BI, A tkins MB . R esistance to targeted therapy in renalcell carcinoma . Lancet Oncol 2009 ; 10 : 992-1000
4. Heng DY, X ie W, R egan MM, G olshayan A R, S ahi C, E igl BJ, et al . Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study . J Clin Oncol 2009 ; 27 : 5794-9
5. Patil S, F iglin R, H utson T, M ichaelson MD, N é grier S, K im ST, et al . Prognostic factors for progression free survival and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma . Ann Oncol 2011 ; 22 : 295-300
6. Motzer R, B acik J, M azumbar M . P rognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan Kettering Cancer Center experience . Clin Cancer Res 2004 : 6202S-3S
7. van der Veldt A A, E echoute K, G elderblom H, G ietema J, Guchelaar HJ, van Erp NP, et al . Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib . Clin Cancer Res 2012 ; 17 : 620-9
8. Garcia-Donas J, E steban E, L eandro-Garcí a LJ, C astellano DE, del Alba AG, Climent MA, et al . Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: A multicentre, observational, prospective study . Lancet Oncol 2011 ; 12 : 1143-50
9. Beuselinck B, K aradimou A, L ambrechts D, C laes B, W olter P, Couchy G, et al . Single nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib . Br J Cancer 2013 (accepted)
10. Xu C F, B ing N X, B all H A, S ternberg C N, H utson T E, de Souza P, et al . Pazopanib efficacy in renal cell carcinoma: Evidence for predictive genetic markers in angiogenesis-related and exposure-related genes . J Clin Oncol 2011 ; 29 : 2557-64
11. Lambrechts D, L enz H-Z, d e Haas S, C armeliet P, S cherer SJ . Markers of response for the anti-Angiogenic agent bevacizumab . J Clin Oncol 2013 (accepted)
12. Hurwitz H, F ehrenbacher L, N ovotny W, C artwright T, Hainsworth J, Heim W, et al . Bevacizumab plus irinotecan, fl uorouracil, and leucovorin for metastatic colorectal cancer . N Engl J Med 2004 ; 350 : 2335-42 (Pubitemid 38702844)
13. Sandler A, G ray R, P erry MC, B rahmer J, S chiller JH, Dowlati A, et al . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer . N Engl J Med 2006 ; 355 : 2542-50 (Pubitemid 44917502)
14. Miller K, W ang M, G ralow J, D ickler M, C obleigh M, P erez EA, et al . Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer . N Engl J Med 2007 ; 357 : 2666-76
15. Escudier B, P luzanska A, K oralewski P, R avaud A, B racarda S, Szczylik C, et al . Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial . Lancet 2007 ; 370 : 2103-11 (Pubitemid 350296300)
16. Kreisl T N, K im L, M oore K, D uic P, R oyce C, S troud I, et al . Phase II trial of single-Agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma . J Clin Oncol 2009 ; 27 : 740-5
17. Lambrechts D, C laes B, D elmar P, R eumers J, M azzone M, Yesilyurt BT, et al . VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: An analysis of data from the AVITA and AVOREN randomised trials . Lancet Oncol 2012 ; 7 : 724-33
18. Hansen TF, C hristensen R D, Andersen R F, G arm Spindler KL, Johnsson A, Jakobsen A . The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: Results from the Nordic ACT trial . Int J Colorectal Dis 2012 ; 6 : 715-20
19. Reumers J, D e Rijk P, Z hao H, L iekens A, S meets D, C leary J, et al . Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing . J Nat Biotechnol 2011 ; 1 : 61-8
20. Beuselinck B, O udard S, R ixe O, W olter P, B lesius A, A yllon J, et al . Negative impact of bone metastasis on outcome in clear cell renal cell carcinoma treated with sunitinib . Ann Oncol 2011 ; 22 : 794-800
21. Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, et al . Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer . J Clin Oncol 2009 ; 27 : 2231-7 .